Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Lewy body dementia

Topic: Amyloid, tau and blood-test diagnosis

Functional impairment increased progressively from normal cognition to dementia. Alzheimer's disease (AD) and frontotemporal dementia (FTD) groups showed significantly greater total PFAQ scores compared to controls and mild cognitive impairment (MCI). Distinct profiles of impairment emerged: AD was more associated with memory-dependent tasks, while FTD showed disproportionate deficits in executive and social activities. Functional abilities are differentially impacted in AD and FTD within the Peruvian population. Our findings highlight the importance of item-level functional evaluation to support early detection and subtype differentiation of dementia in underserved regions. HIGHLIGHTS: We characterized and compared functional abilities among Peruvian older adults with normal cognition and neurodegenerative disease in different stages. PFAQ scores were analyzed across dementia stages in a Peruvian population. Functional abilities were differentially impacted in Peruvian participants with AD compared to FTD. AD was more associated with memory-dependent tasks, while FTD showed disproportional deficits in executive and social activities.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Custodio, N., Brown, G. L., Custodio, B., Montesinos, R., Nuñez-Huanca, M., Bartolo, P., et al. (2025). Functional capacity in Peruvian people with Alzheimer's disease and frontotemporal dementia. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70979

Vancouver

Custodio N, Brown GL, Custodio B, Montesinos R, Nuñez-Huanca M, Bartolo P, et al. Functional capacity in Peruvian people with Alzheimer's disease and frontotemporal dementia. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70979. PMID: 41400005.

BibTeX

@article{custodio2025-41400005,
  author  = {Custodio, Nilton and Brown, Gregory L. and Custodio, Belén and Montesinos, Rosa and Nuñez-Huanca, Milagros and Bartolo, Pamela and Yauri, Zadith and Agüero, Katherine and others},
  title   = {{Functional capacity in Peruvian people with Alzheimer's disease and frontotemporal dementia}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70979},
  pmid    = {41400005},
  url     = {https://doi.org/10.1002/alz.70979}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This cross-sectional study found that functional impairment increased progressively from normal cognition to dementia, with Alzheimer's disease more associated with memory-dependent tasks and frontotemporal dementia showing disproportionate deficits in executive and social activities. It is about functional profiles, not about treating, curing or preventing dementia.

Study details

How this study scored 50/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 4 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 50 of 100.50 of 100 points earned50 not earned

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 3 / 4 1,445 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 3 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Agustín M. Ibáñez: h-index 81 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 7 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41400005)
Free to read 2 / 2 Free to read
Total 50 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Lewy body dementia

Also tagged “bodies”

1,017 studies in the library carry the topic tag “bodies”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Lewy body dementia

See all studies in Lewy body dementia →